Tags

Type your tag names separated by a space and hit enter

The emerging role of cannabinoid neuromodulators in symptom management.

Abstract

INTRODUCTION

The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy.

DISCUSSION

The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain.

SUMMARY

The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    The Harry R. Horvitz Center for Palliative Medicine, Cleveland Clinic, Cleveland, OH 44195, USA. davism6@ccf.org

    , ,

    Source

    MeSH

    Administration, Oral
    Analgesics, Non-Narcotic
    Antiemetics
    Antineoplastic Agents
    Breast Neoplasms
    Dronabinol
    Female
    Humans
    Middle Aged
    Pain
    Receptors, Cannabinoid
    Spinal Neoplasms
    Vomiting

    Pub Type(s)

    Case Reports
    Journal Article
    Review

    Language

    eng

    PubMed ID

    17139494

    Citation

    Davis, Mellar, et al. "The Emerging Role of Cannabinoid Neuromodulators in Symptom Management." Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, vol. 15, no. 1, 2007, pp. 63-71.
    Davis M, Maida V, Daeninck P, et al. The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007;15(1):63-71.
    Davis, M., Maida, V., Daeninck, P., & Pergolizzi, J. (2007). The emerging role of cannabinoid neuromodulators in symptom management. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 15(1), pp. 63-71.
    Davis M, et al. The Emerging Role of Cannabinoid Neuromodulators in Symptom Management. Support Care Cancer. 2007;15(1):63-71. PubMed PMID: 17139494.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The emerging role of cannabinoid neuromodulators in symptom management. AU - Davis,Mellar, AU - Maida,Vincent, AU - Daeninck,Paul, AU - Pergolizzi,Joseph, Y1 - 2006/12/01/ PY - 2006/09/27/received PY - 2006/10/09/accepted PY - 2006/12/2/pubmed PY - 2007/4/6/medline PY - 2006/12/2/entrez SP - 63 EP - 71 JF - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JO - Support Care Cancer VL - 15 IS - 1 N2 - INTRODUCTION: The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. DISCUSSION: The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain. SUMMARY: The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models. SN - 0941-4355 UR - https://www.unboundmedicine.com/medline/citation/17139494/The_emerging_role_of_cannabinoid_neuromodulators_in_symptom_management_ L2 - https://dx.doi.org/10.1007/s00520-006-0180-0 DB - PRIME DP - Unbound Medicine ER -